cGAS-STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapyOA
The cyclic GMP-AMP synthase-stimulator of interferon genes(cGAS-STING)pathway is a central sensor of innate immunity that plays critical roles in recognizing cytosolic DNA and initiating antitumor immune responses.However,this pathway exhibits extensive spatiotemporal duality and context dependency in tumor regulation.In recent years,modulating this pathway to convert immunologically“cold”tumors into immunologically“hot,”inflamed tumors has emerged as a cutting-edge strategy to reverse resistance to immune checkpoint inhibitors(ICIs).This review outlines the molecular mechanisms underlying the activation and regulation of the cGAS-STING pathway,with emphasis on its complex role in orchestrating the tumor immune phenotypic switch.A nuanced analysis of the pathway’s duality distinguishes between acute immunostimulatory activation and chronic,protumorigenic inflammation driven by chromosomal instability(CIN).Furthermore,current evidence regarding direct and indirect T-cell modulation,as well as pathway-mediated remodeling of the tumor microenvironment(TME)across diverse malignancies,is discussed in detail.Crucially,the current bottlenecks in clinical translation are described,including evaluation of the failure of first-generation agonists and the promise of next-generation delivery platforms such as antibody-drug conjugates(ADCs)and nanoparticle systems.Finally,a novel strategic framework is proposed involving mapping of specific STING-targeted modalities to distinct TME phenotypes,such as immune-desert,immune-excluded,and exhausted-inflamed states.A detailed understanding of the cGAS-STING axis has substantial value in providing theoretical guidance and supporting clinical translation in the development of next-generation combination immunotherapies,as well as broadening the patient population benefiting from clinical interventions.
Xinru Zhao;Shuai Meng;Hanzeng Cheng;Haixia Yu;Meiting Rong;Chao Zhang;Cien Qiu;Jie Zhang;Chunnuan Wu;Wenxia Zhao
School of Chinese Materia Medica,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China Department of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaDepartment of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaDepartment of Pharmacy,Tianjin First Central Hospital,Tianjin 300192,ChinaDepartment of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaDepartment of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaDepartment of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaSchool of Chinese Materia Medica,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China Department of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaDepartment of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaDepartment of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,ChinaDepartment of Pharmacy,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,China
医药卫生
cGAS-STING pathwaytumor microenvironmentcold-to-hot tumor transitionimmunotherapySTING agonists
《Cancer Biology & Medicine》 2026 (9)
P.1250-1282,33
supported by the National Natural Science Foundation of China(Grant No.82504823)Natural Science Foundation of Tianjin(Grant Nos.25JCQNJC00590 and 25JCLMJC00560)Tianjin Key Medical Discipline Construction Project(Grant No.TJYXZDXK-3-003A).
评论